Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach
- PMID: 36802013
- PMCID: PMC10250517
- DOI: 10.1007/s12094-023-03112-w
Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach
Abstract
Background: Precision medicine in oncology aims to identify the most beneficial interventions based on a patient's individual features and disease. However, disparities exist when providing cancer care to patients based on an individual's sex.
Objective: To discuss how sex differences impact the epidemiology, pathophysiology, clinical manifestations, disease progression, and response to treatment, with a focus on data from Spain.
Results: Genetic and environmental factors (social or economic inequalities, power imbalances, and discrimination) that contribute to these differences adversely affect cancer patient health outcomes. Increased health professional awareness of sex differences is essential to the success of translational research and clinical oncological care.
Conclusions: The Sociedad Española de Oncología Médica created a Task Force group to raise oncologists' awareness and to implement measures to address sex differences in cancer patient management in Spain. This is a necessary and fundamental step towards optimizing precision medicine that will benefit all individuals equally and equitably.
Keywords: Cancer; Epidemiology; Female; Male; Sex; Treatment.
© 2023. The Author(s).
Conflict of interest statement
Ruth Vera has received honoraria from or acted in an advisory role for Roche, Sanofi, MSD, Merck, Eisai, Novartis, Pierre Fabre, Lilly, BAXTER, and ABBOTT, funding for educational or research programmes from Roche, Lilly and MSD, as well as payment of travel/accommodation expenses from Roche, Merck, Sanofi, Pierre Fabre, and MSD. Oscar Juan-Vidal has received honoraria from or acted in an advisory role for Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, AstraZeneca, Pfizer, Eli Lilly, AbbVie, and Takeda, and has received travel/accommodation expenses from Takeda and AstraZeneca. María José Safont Aguilera has received honoraria from or acted in an advisory role for Amgen, Merck, Servier, and Pierre Fabre, and travel/accommodation expenses from Amgen, Merck and Servier. Francisco Ayala de la Peña has received honoraria from or acted in an advisory role for AstraZeneca, Celgene, Eisai, Novartis, Roche, Pfizer, Pierre Fabre, Lilly, Sanofi, Seagen, and Daichi-Sankyo, funding for educational or research programmes from Celgene, Roche, and MSD, and travel/accommodation expenses from Roche, Pfizer, Celgene, Eisai, Pfizer, Pierre Fabre, and MSD. Aránzazu González del Alba has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer, MSD and Ipsen and honoraria for speaker engagements, advisory boards and continuous medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Eusa Pharma, Eisai, Novartis, AAA and AstraZeneca.
Figures

Similar articles
-
[Consensus on hereditary cancer between the Spanish Oncology Society and the primary care societies].Semergen. 2013 Jul-Aug;39(5):259-66. doi: 10.1016/j.semerg.2012.08.007. Epub 2013 Mar 13. Semergen. 2013. PMID: 23834976 Spanish.
-
Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study.Adv Ther. 2021 Jan;38(1):290-303. doi: 10.1007/s12325-020-01532-6. Epub 2020 Oct 27. Adv Ther. 2021. PMID: 33111255
-
Sexual health after breast cancer: Recommendations from the Spanish Menopause Society, Federación Española de Sociedades de Sexología, Sociedad Española de Médicos de Atención Primaria and Sociedad Española de Oncología Médica.Maturitas. 2017 Nov;105:126-131. doi: 10.1016/j.maturitas.2017.02.010. Epub 2017 Feb 20. Maturitas. 2017. PMID: 28268037 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.J Clin Oncol. 2003 Jun 15;21(12):2397-406. doi: 10.1200/JCO.2003.03.189. Epub 2003 Apr 11. J Clin Oncol. 2003. PMID: 12692171
Cited by
-
A Pan-Cancer Analysis of Age and Sex Differences in Cancer Incidence and Survival in the United States, 2001-2020.Cancers (Basel). 2025 Jan 24;17(3):378. doi: 10.3390/cancers17030378. Cancers (Basel). 2025. PMID: 39941747 Free PMC article.
-
Sex-Based Differences in Medullary Thyroid Cancer Survival: A Matched Analysis of 4602 Patients.Ann Surg Oncol. 2025 Aug 21. doi: 10.1245/s10434-025-18067-1. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40839143
-
Sex differences in presentation of pheochromocytoma and paraganglioma.Front Endocrinol (Lausanne). 2025 Jan 23;16:1463945. doi: 10.3389/fendo.2025.1463945. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 39917539 Free PMC article.
-
Sex-specific outcomes in cancer therapy: the central role of hormones.Front Med Technol. 2024 Feb 1;6:1320690. doi: 10.3389/fmedt.2024.1320690. eCollection 2024. Front Med Technol. 2024. PMID: 38362126 Free PMC article. Review.
-
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?ESC Heart Fail. 2025 Apr;12(2):1447-1454. doi: 10.1002/ehf2.15165. Epub 2025 Jan 9. ESC Heart Fail. 2025. PMID: 39780756 Free PMC article.
References
-
- Office of Research on Women's Health. Sex & gender. 2022. https://orwh.od.nih.gov/sex-gender#:~:text=%22Sex%22%20refers%20to%20bio.... Accessed July 12, 2022.
-
- World Health Organization. Gender and health. 2022. https://www.who.int/health-topics/gender#tab=tab_1. Accessed July 12, 2022.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical